Purevax Rabies
rabies recombinant canarypox virus (vCP65)
Table of contents
Overview
Purevax Rabies is a veterinary vaccine used to protect cats from 12 weeks of age against rabies infection. It contains rabies recombinant canarypox virus (vCP65).
Authorisation details
Product details | |
---|---|
Name |
Purevax Rabies
|
Agency product number |
EMEA/V/C/002003
|
Active substance |
vCP65 virus
|
International non-proprietary name (INN) or common name |
rabies recombinant canarypox virus (vCP65)
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AX
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
18/02/2011
|
Contact address |
55216 Ingelheim am Rhein |
Product information
14/08/2020 Purevax Rabies - EMEA/V/C/002003 - IG/1279
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.
Onset of immunity: 4 weeks after the primary vaccination course.
Duration of immunity after primary vaccination: 1 year.
Duration of immunity after revaccination: 3 years.